

Animal Reproduction Research Institute,
El-Haram, Giza, Egypt.
Director: Prof. Dr. N.A. El-Danaf.

ROLE OF OXYTETRACYCLINE IN LIVER DYSFUNCTION OF EGYPTIAN BUFFALO CALVES

(With 3 Tables)

By

HASSAN, H.M. ; NASSER, M.H.* and EMARA S.A.

(Received at 27/7/1995)

دور الأوكسي تتراسيكلين فى خلل وظائف الكبد فى عجول الجاموس
هاتى حسن ، محمد ناصر ، وسميرة عمارة

اجرى هذا البحث على عدد ١٢ عجل جاموس (عمر ١-٢ شهرا) سليم اكلينيكيا حيث قسمت العجول الى مجموعتين متساويتين . المجموعة الاولى كانت المجموعة التجريبية التى حقنت بجرعة قدرها ٢٠٠ ملجرام من الأوكسي تتراسيكلين لكل ١٠ كجم من الوزن الحى بالحقن العضلى مرة واحدة والمجموعة الثانية لم تحقن سوى محلول الملح الفسيولوجى واستعملت كمجموعة ضابطة . هذا وقد اتضح ان حقن عجول الجاموس بجرعة علاجية من عقار الأوكسي تتراسيكلين تودى الى زيادة معنوية فى مستوى أنزيمى الترانس أمينيز . وأنزيم الفوسفاتيز القاعدى . الدهون الكلية ، الكوليسترول ، وكذلك فى مستوى نسبة البيلروبين الكلى . وهذه التغيرات وجد أنها تستمر لمدة اسبوعين . وعلى نفس المستوى ، وجد ان عقار الأوكسي تتراسيكلين قد أحدث زيادة فى انزيم الارجينيز التى استمرت لمدة اسبوع . وفى اطار نفس التجربة اظهرت المجموعة المعالجة بعقار الأوكسي تتراسيكلين ارتفاعا معنويا فى مستوى جلوكوز الدم لمدة اسبوع بعد المعالجة . وعلى النقيض ، أحدث الحقن بعقار الأوكسي تتراسيكلين فى عجول الجاموس انخفاضا معنويا فى مستوى البروتين الكلى والجلوبيولين وذلك لمدة اسبوعين بينما لم يحدث اى تغيرات معنوية فى مستوى الالبومين .

SUMMARY

This work was carried on 12 clinically healthy buffalo calves (1-2 month old) divided into 2 equal groups. The first group was the experimental group where single intramuscular injection of 20 mg oxytetracycline base /kg body weight was given to each animal. The second group used as control and was injected on normal physiological saline solution. In buffalo calves of the first group single intramuscular injection dose of oxytetracycline evoked a significant increase ($P < 0.05$) in blood serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), Alkaline phosphatase (ALP) activities, total lipids, total cholesterol and serum total bilirubin levels. The previous changes lasted for two weeks. On the similar grounds, oxytetracycline administration induced an elevation of serum arginase activity that lasted for one week. In keeping with this line, oxytetracycline treated group displayed

* Faculty of Veterinary Medicine, Tanta University, Kafr El Sheikh branch.

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

a significant increase ($P < 0.05$) of blood serum glucose level for one week post treatment. Conversely, oxytetracycline injection produced a significant decline ($P < 0.05$) of blood serum total protein and globulin levels for two weeks. Meanwhile oxytetracycline induced non significant changes in blood serum albumin levels in the treated buffalo calves.

Keywords: Role, oxytetracycline, liver dysfunction, Egyptian buffalo-calves

INTRODUCTION

Oxytetracycline is a member of a group of antibiotics produced by a strain of *Streptomyces rinosus* and belongs to the tetracycline group. It is a broad spectrum antibiotic used for treatment of both gram positive and gram negative bacterial infections in animals. The drug is used against mycoplasma, rickettsia and clamidia diseases (SANDE and MANDELL, 1991). The use of tetracyclines is now discouraged due to problems of bacteria resistance (TROLLE-NIER, 1980 and HARVEY, 1980). Toxic effect induced on different organs of the body, especially the liver and kidneys in camel (EL-ATRASH, 1983) and in goat (AZOOZ, 1994) were also established.

The present study was carried out to investigate the possible adverse effects, if any, of oxy-tetracycline treatment in buffalo calves. eventually to address the validity of the promising future use of this drug in calves.

MATERIAL and METHODS

1-Drug: Oxytetracycline dihydrate (Terramycin/LA[®]- Pfizer Egypt) equivalent to 200 mg. oxytetracycline base/ml as mag-nesium complex in an aqueous solution, was used in this study.

2- Animals: Twelve, 1-2 month old buffalo calves were experimented. These animals proved to be clinically healthy by cili-nical examination. Laboratory findings which ascertained that such animals were free from both internal and exeternal parasites. Case history of these animals indicated that they were not subjected to medications for at least 35 days before the present experimentation. Animals were then randomly classified into two equal groups. The first group was intramuscularly injected with one dose of 200mg oxytetracycline/10 Kg body weight (1ML/10 Kg body weight). The 2nd group was kept as control and injected with normal saline.

3- Sampling: Blood samples were collected from the jugular vein 1/2 hour (h.) before treatment, 2h., 6 h., 12 h., 24 h., 3 days, one week, 2 weeks and 3 weeks post treatment. The samples were left to clot and centrifuged at 3000 r.p.m. for 15 minutes. The separated serum samples were stored at -20°C for biochemical analysis.

4- Biochemical analysis: Blood serum samples were analyzed for aspartate amino transferase (AST); alanine amino transferase (ALT) activities;

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

alkaline phosphatase activity (REJ and HORDER, 1983), total bilirubin (MALLORY and EVELYN, 1937); glucose (DUBOWSKI, 1962); total cholesterol (WATSON, 1960); total lipids (ZOLLNER and KIRSCH, 1962); total proteins (KING and WOOTTON, 1959); albumin; globulins levels (rEINHOLD, 1953) and arginase activity (MIA and KOGER, 1978).

5- Statistical analysis: The results are represented as the mean \pm S.E.. Statistical significance was determined by Student's (t) test for paired observations according to SNEDECOR (1971).

RESULTS

Data presented in table (1) revealed that 6 hours post oxy-tetracycline injection evoked a significant increase ($P < 0.05$) in ALT, AST and ALP activities was recorded. The previous increases lasted for two weeks, achieving nearly the normal control levels after the 3rd. week post injection. Arginase activity displayed a significant elevation, 2 hours post treatment, that persisted so till the 1st. week but declined thereafter to reach nearly the normal control level at the 2nd. week post injection when compared with the control group.

Table (2) showed that oxytetracycline induced a marked augmentation ($P < 0.05$) of total lipids, total cholesterol, and total bilirubin levels for two weeks post treatment. Elevated glucose level persisted till one week post treatment.

Oxytetracycline treated group exhibited a significant ($P < 0.05$) reduction of serum total proteins and globulins levels after 3 days, that was clearly prevailed through the 2nd. week. On the 3rd week, the previous changes restored nearly its normal control level values. On the other hand, oxy-tetracycline evoked no significant changes in albumin levels as compared with respective control values (Table 3).

DISCUSSION

In the present study, it has been found that in buffalo calves, single injection of oxytetracycline elicited a significant increase in ALT, AST, Alkaline phosphatase activities, Total Cholesterol, Total lipids, Total bilirubin and Glucose values with a significant decrease ($P < 0.05$) in serum total protein and globulins levels.

Unfortunately, our data don't provide us with a ready explanation for the previous changes, nevertheless, a number of proposal worth discussion could be stated.

Serum alkaline phosphatase activity is of some value in the diagnosis of bile duct obstruction in both cats and dogs. Alkaline phosphatase activity level increases in early hepatic damage and is particularly valuable in the fatty liver change associated with diabetes militus (DOXEY, 1983). Values also increased when the liver was congested or exposed to toxin (CORNELIUS, 1989). In chronic active hepatitis and hepatocellular carcinoma, the levels also increases (STRO-MBECK, 1978 and STROMBECK and GRIBBLE, 1978).

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

High serum levels are seen in cases of acute hepatic damage (*TROMBECK and GRIBBLE, 1978*). Serum alkaline phosphatase activity levels are elevated in cases of acute pancreatitis (*SCHAER, 1979*). The enzyme level tend to rise in association with increase osteoblast activity but the increase seen in bone disorder is not specific for any particular disorder (*DOXEY, 1983*). Alkaline phosphatase enzyme is excreted in the bile and so circulating value will increase in cases of liver damage particularly of biliary or intrahepatic obstructive types as well as in instances of excessive bone activities (*FREEDLAND et al., 1965*).

It is proposed that increased serum AST activity is shown following muscular damage, liver damage, myocardial infarction and exposure to various chemicals and drugs (*KANEKO, 1989*). Another possible explanation is cellular destruction in several extra-hepatic tissues and thus elevated serum AST activity level is shown to be non specific for hepatic tissue damage (*VARELY et al., 1980*).

In dogs, cardiac damage of an acute nature results in a marked rise in serum activity levels of ALT. However, similar results are obtained with muscular or liver damage. Most cases of acute pancreatitis exhibit high level of serum ALT activity (*DOXEY, 1983*).

Arginase serum level will rise rapidly following acute hepatic damage (*SODIKOFF, 1980*).

In hyperlipimia there appear to be excessive fat mobilization, which iris in

free fatty acids levels, with evidence of liver damage (*DOXEY, 1983*).

Hypercholesteremia, is found in nephrotic syndrome, nephritis, obstructive jaundice, diabetes mel-litus, acidosis, hepatocellular damage, hyperthyroidism and pancreatitis (*VARELY et al., 1980*).

Hypoproteinemia occurs in failure of parenchymal synthesis of serum amino acids, portal cirrho-sis, renal diseases (Glomerulonephritis), nephrotic syndrome, pancreatic hypoplasia or atrophy, diabetes mellitus and increase protein breakdown for gluconeogenesis (*BENJAMIN, 1979*).

Serum bilirubin levels increase in any forms of jaundice and hepatocellular damage (*SOVA, 1965*).

Given this framework, how our data can be interpreted?. It is tempting to suggest that the forementioned alterations are imp-utable, at least in part, to a pro-posed adverse effect of oxytet-racycline exerted exclusively on hepatic tissues.

In support of the previous concept, is the fact that oxytetra-cycline dose inhibit liver mitochondrial oxidative phosphorylation (*Dubuy and Showacare, 1961*). On similar grounds, it is proposed that inhibition of protein synthesis is the initial step in pathogenesis of tetracyclines inducing fatty changes in hepatocytcs (*YEH and SHILS, 1966 and ZIA and PRICE, 1976*). Needless to say, our data reinforced those previously documented with oxy-tetracycline treatment in camels (*EL-ATRASH, 1983*) and goats (*AZOOZ, 1994*).

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

The hypoproteinemia and hypoglobulinemia observed in this study could be viewed in the light of significant inhibitory effect of oxytetracycline on the protein synthesis of mammalian cells and reduction of β cell activity and ultimately antibody reduction (BANCKS and FORSGREN, 1979 and HASSAN, 1994).

Summing up our observations, it could be concluded that this study represented

a further image of the hazardous effect of oxytetracycline therapy in buffalo calves that would ultimately be mirrored as liver dysfunction. In keeping with this line, the present study imposes much weight on the argument against the fact that oxytetracycline is the drug of choice in bacterial infection of buffalo calves.

REFERENCES

- Azooz, H.A. (1994): Pharmacokinetic and biochemical aspects of some antibiotics in goats. Ph.D. thesis (Pharmacology), Fac. Vet. Med., Cairo Univ.
- Benjamin, M.M. (1979): Outline of Veterinary Clinical Pathology. 3rd. Ed. the Iowa State University Press. Ames, Iowa, USA.
- Cornelius, C.E. (1989): Liver function, In Clinical Biochemistry in Domestic Animals, 4th. Ed. by Academic Press. USA.
- Doxey, D.L. (1983): Clinical Pathology and Diagnostic Procedures. 2nd. Ed. Billiere Tindall- London.
- Dubowski, K.M. (1962): An O-Toluidine method for body fluid glucose determination. Clin. Chem., 8:215-235.
- Dubuy, H.G. and Showacare, J.H. (1961): Selective localization of tetracycline in mitochondria of living cells. Science, 183, 196 - 197.
- El-Atrash, S.A. (1983): Changes in blood of camels following antibiotic therapy. Ph.D. thesis (Pharmacology), Fac. Vet. Med., Cairo Univ.
- Freedland, R.A.; Jerpe, C.A. and Cornelius, C.E. (1965): Comparative studies on plasma enzyme activities in hepatic necrosis in horse. Res. Vet. Sci. 6, 18- 23.
- Harvey, S.C. (1980): Remington's Pharmaceutical Science, 16 th. Ed. Mack Pup. Co., Pennsylvania -USA.
- Hassan, H.M. (1994): Effect of Some chemotherapeutic agents on the immunocompetence and reproductive performance of Egyptian buffalo, Ph.D. Thesis, Pharmacology Dept., Fac. of Vet. Medicine, Zgagiz University.
- Kaneko, J. (1989): Clinical Biochemistry of Domestic Animals. 4th. Ed. Academic Press, San Diago- New York- Toronto - London - Tokyo.
- King, E.J. and Wootton, I.O. (1959): Micromethods in Medical Biochemistry. 3rd. Ed. Churchill, London.

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

- Mallory, H.T. and Evelyn, K.A. (1937):* The Determination of bilirubin with the photometric colorimetric. *J. Biol. Chem.* 119: 481 - 485.
- Mia, A.S. and Koger, H.D. (1978):* Direct colorimetric determination of serum arginase in various domestic animals. *Am.J. of Vet.Res.* 39:1381-1384.
- Reinhold, J.G. (1953):* Standard Methods of Clinical Chemistry. Academic Press, New York 88-97.
- Rej, R.I. and Horder, D. (1983):* In Methods of Enzymatic Analysis (V. Bergmeyer, J. Bergmeyer and M. Garbl) 3rd. Ed. Vol I, Verlage Chemie, Deerfield Beach, Florida
- Sande, M.A. and Mandell, G.L. (1991):* Antimicrobial agents. Goodman Gilman's the pharmacological basis of therapeutics, Eighth Ed., McGraw-Hill International Edition Medical Series.
- Schaer, M. (1979):* A cute clinicopathological survey of acute pancreatitis in 30 dogs and 5 cats. *J. Am. Anim. Hosp. Ass.*, 15, 681- 687.
- Snedecor, G.W. (1971):* Statistical Methods. 14 th. Ed. The Iowa State College Press. Ames. Iowa.
- Sodikoff, C. (1980):* Arginase: a liver specific enzyme. *Med. Vet. Pract.*, 61: 135-137.
- Sova, Z. (1965):* Laboratory diagnosis of acute liver damage in horse. *Vet Med. (Praha)* 10, 465-476.
- Strombeck, D.R. (1978):* Clinicopathological features of primary and metastatic neoplastic disease of liver in dogs. *J. Am. Vet. Med. Ass.*, 173, 267-269.
- Strombeck, D.R. and Gribble, D. (1978):* Chronic active hepatitis in Dogs. *J. Am. Vet. Med. Ass.*, 173, 380- 386.
- Trollenier, H. (1980):* Development of drug resistance among pathogenic bacteria obtained from veterinary examinations between 1971 and 1977. *Mh. Vet.*; 35: 460-467
- Varely, H. Gowenlock, A. and Bell, M. (1980):* Practical Clinical Biochemistry. William Heinemann. Medical Book, LTD. London
- Watson, D. (1960):* Colorimetric determination of cholesterol. *Clinic. Acta.* 5: 637-642.
- Yeh, S.D. and Shils, M.E. (1966):* Tetracycline and incorporation of amino acids into proteins of rat tissues. *Proc. Soc. Exp. Biol. Med.*, 121, 729-936.
- Zia, H. and Price, J.C. (1976):* Binding study of tetracyclines to human serum albumin using different spectrophotometry. *J. Pharmacology. Sci.*, 65, 226-230
- Zollner, N. and Kirsch, K. (1962):* Determination of serum lipids. *Exper. Med.* 135:545-551

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

Table (1) : Effect of oxytetracycline treatment on the level of blood serum AST, ALT, Alkaline phosphatase (ALP) and Arginase in buffalo calves.
(U/Lit.) (n = 6 / group) (Mean ± S.E.)

TIME POST TREATMENT	CONTROL GROUP				TREATED GROUP			
	AST	ALT	ALP.	ARGINASE	AST	ALT	ALP.	ARGINASE
pretreatment	90.80 ± 9.62	22.28 ± 2.93	63.4 ± 5.6	5.13 ± 0.12	83.64 ± 11.82	23.81 ± 3.71	67.2 ± 10.6	6.72 ± 0.88
2h.	81.72 ± 7.30	21.98 ± 3.32	64.2 ± 7.2	4.35 ± 0.72	105.42 ± 15.22	22.39 ± 2.93	76.0 ± 12.4	8.73 ± 1.10*
6h.	97.16 ± 9.81	22.40 ± 2.28	60.2 ± 9.2	6.18 ± 0.45	133.26 ± 9.32*	32.66 ± 1.33*	178.4 ± 19.8*	9.83 ± 1.02*
12h.	94.96 ± 8.50	23.82 ± 2.50	69.0 ± 4.6	4.52 ± 0.63	157.2 ± 11.00*	31.33 ± 2.23*	146.4 ± 8.4*	13.65 ± 0.52*
24h.	90.88 ± 6.66	21.73 ± 2.39	60.4 ± 7.6	5.32 ± 0.56	161.8 ± 15.34*	35.16 ± 3.56*	171.2 ± 21.3*	13.12 ± 0.83*
3days	101.2 ± 9.62	23.11 ± 3.33	64.6 ± 8.4	5.86 ± 0.51	178.07 ± 14.8*	33.33 ± 1.44*	177.0 ± 16.7*	13.51 ± 0.33*
one week	104.0 ± 6.42	20.22 ± 2.56	72.4 ± 7.9	6.21 ± 0.32	169.13 ± 11.3*	36.65 ± 2.32*	172.6 ± 26.8*	15.72 ± 0.85*
two weeks	86.73 ± 6.22	22.31 ± 2.88	71.8 ± 6.4	5.68 ± 0.47	163.41 ± 10.8*	34.51 ± 3.37*	148.0 ± 18.5*	8.02 ± 1.73
three weeks	97.32 ± 7.84	24.56 ± 3.97	68.7 ± 7.8	4.72 ± 0.45	120.62 ± 20.2	30.36 ± 3.33	105.2 ± 26.1	6.11 ± 0.68

* : Significant at P < 0.05

OXYTETRACYCLINE, LIVER DYSFUNCTION & BUFFALO CALVES

Table (2) : Effect of oxytetracycline treatment on the level of blood serum Total lipids (T.Lipids) , Total cholesterol (T.Cholest.) , Glucose and Total bilirubin (T.bil.) in buffalo calves . (mg / 100 ml) (n = 6 / group) (Mean \pm S.E.)

TIME POST TREATMENT	CONTROL GROUP					TREATED GROUP				
	T. LIPIDS	CHOLEST.	GLUCOSE	T. BIL.	T. LIPIDS	GLUCOSE	T. BIL.	T. LIPIDS	GLUCOSE	T. BIL.
pretreatment	633 \pm 52.1	105 \pm 16.2	111 \pm 12	0.37 \pm 0.05	605 \pm 41	107 \pm 12	0.45 \pm 0.06			
2h.	640 \pm 61	113 \pm 10.2	95 \pm 6.5	0.32 \pm 0.03	657 \pm 82	100 \pm 18	0.51 \pm 0.15			
6h.	621 \pm 65	102 \pm 7.6	104 \pm 8.6	0.35 \pm 0.05	673 \pm 65	134 \pm 12.5	0.73 \pm 0.12*			
12h.	635 \pm 72	114 \pm 8.8	97 \pm 7.7	0.38 \pm 0.01	685 \pm 61	145 \pm 11.3*	1.52 \pm 0.09*			
24h.	505 \pm 67	100 \pm 12.0	123 \pm 11.5	0.31 \pm 0.07	788 \pm 33*	176 \pm 8.3*	1.62 \pm 0.11*			
3days	515 \pm 58	98 \pm 8.5	115 \pm 10.3	0.29 \pm 0.06	819 \pm 57*	182 \pm 10.7*	1.36 \pm 0.07*			
one week	676 \pm 72	121 \pm 16.3	106 \pm 8.6	0.37 \pm 0.03	925 \pm 59*	187 \pm 11.5*	1.07 \pm 0.15*			
two weeks	613 \pm 29	104 \pm 7.3	126 \pm 13.2	0.40 \pm 0.02	882 \pm 72*	115 \pm 18.3	1.38 \pm 0.17*			
three weeks	588 \pm 67	109 \pm 13.8	118 \pm 16.5	0.35 \pm 0.09	761 \pm 55	135 \pm 28.6	0.56 \pm 0.13			

* : Significant at P < 0.05

Table (3) : Effect of oxytetracycline treatment on the level of blood serum total proteins (T.P.), albumin (Alb.) and globulins (Glb.) in buffalo calves.
(gm / 100 ml.) (n = 6 / group) (Mean \pm S.E.)

TIME POST TREATMENT	Control Group			Treated Group		
	T.P.	ALB.	GLB.	T.P.	ALB.	GLB.
pretreatment	7.62 \pm 1.03	3.35 \pm 0.62	3.65 \pm 0.27	6.89 \pm 0.47	3.29 \pm 0.25	3.58 \pm 0.41
2h.	7.53 \pm 0.82	3.15 \pm 0.32	3.58 \pm 0.28	7.02 \pm 0.52	3.31 \pm 0.36	3.71 \pm 0.23
6h.	7.77 \pm 0.65	3.72 \pm 0.25	4.02 \pm 0.35	6.88 \pm 0.60	3.41 \pm 0.51	3.50 \pm 0.58
12h.	6.81 \pm 0.75	2.66 \pm 0.30	4.15 \pm 0.47	6.42 \pm 0.33	3.32 \pm 0.30	3.36 \pm 0.43
24h.	6.74 \pm 0.42	2.85 \pm 0.28	4.10 \pm 0.35	5.62 \pm 0.63	3.05 \pm 0.42	2.46 \pm 0.83
3 days	6.96 \pm 0.58	2.93 \pm 0.31	3.04 \pm 0.21	5.11 \pm 0.06*	3.15 \pm 0.16	2.09 \pm 0.22*
one week	7.23 \pm 0.81	3.33 \pm 0.27	4.09 \pm 0.17	5.20 \pm 0.11*	3.26 \pm 0.47	2.11 \pm 0.05*
two weeks	6.58 \pm 0.72	2.92 \pm 0.32	3.88 \pm 0.45	5.01 \pm 0.03*	3.15 \pm 0.38	2.03 \pm 0.06*
three weeks	7.35 \pm 1.31	3.38 \pm 0.45	3.96 \pm 0.23	6.33 \pm 0.71	3.16 \pm 0.52	3.33 \pm 0.47

* : Significant at P < 0.05